Transmedics Group, Inc. · NASDAQ:TMDX

Transmedics — Baird 2026 Global Healthcare Conference

14 slides from Transmedics's conference presentation, September 2026

  1. Slide 1: The End of Transplant Waiting List

    NASDAQ • TMDX The End of Transplant Waiting List Portable warm perfusion technology. A national service & logistics network. A command-and-control platform. One purpose — every viable organ, every patient, every time Waleed Hassanein, MD Founder, President & Chief Executive Officer September 2026 86

  2. Slide 2: Cautionary Note Regarding Forward Looking Statements

    Cautionary Note Regarding Forward Looking Statements This presentation contains forward-looking statements. These forward-looking statements address various matters, including, among other things, future results and events, including financial guidance and projected estimates, potential timelines fo

  3. Slide 3: Transplantation: The Gold Standard, Highest Value Solution for End Stage Organ Failure

    Transplantation: The Gold Standard, Highest Value Solution for End Stage Organ Failure — Severely Supply Constrained Market CLINICAL OUTCOME ECONOMIC PROFILE MARKET STRUCTURE Gold Standard Cost Effective Supply Constrained Best long-term survival and quality Cost-effective vs. dialysis and Donor org

  4. Slide 4: Vertically Integrated Moat — Five Layers Deep - Difficult to Replicate

    Vertically Integrated Moat — Five Layers Deep - Difficult to Replicate 01 OCS Technology 02 NOP Service Technology 03 Logistics Network platform National clinical 04 NOP Connect infrastructure Air & ground 05 Donor Screening Portable warm perfusion logistics network preserves and assesses Turnkey pr

  5. Slide 5: A Proven Operating Model — Scaled to Profitability, Financing our Growth Initiatives

    A Proven Operating Model — Scaled to Profitability, Financing our Growth Initiatives REVENUE • ($M) Adj. OPERATING INCOME • ($M) $94M → $605M in three years $112.2 $605 $442 $37 $242 $94 ($31) ($29) FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 86% revenue CAGR FY22–FY25 • driven by NOP scale-up and OCS H

  6. Slide 6: OCS Platform — The only FDA-approved Portable Warm Multi-Organ Perfusion Platform

    OCS Platform — The only FDA-approved Portable Warm Multi-Organ Perfusion Platform OCS LUNG OCS HEART OCS LIVER OCS KIDNEY FDA-APPROVED FDA-APPROVED FDA-APPROVED IN DEVELOPMENT 6

  7. Slide 7: National OCS Program — Integrated Tech., Procurement & Clinical Service, and Logistics Network Infrastructure

    National OCS Program — Integrated Tech., Procurement & Clinical Service, and Logistics Network Infrastructure 20 22 50+ 250+ Clinical NOP hubs Transplant aircraft Procurement surgeons Clinical specialists nationwide U.S. footprint + 140 dedicated pilots dedicated to OCS cases OCS specialists & coord

  8. Slide 8: Secure Purpose-Built Digital Ecosystem — NOP Connect Real-time Visibility for Every Stakeholder

    Secure Purpose-Built Digital Ecosystem — NOP Connect Real-time Visibility for Every Stakeholder 01 Logistics Optimization Engine 02 Transplant Center Portal 03 Automated Scheduling Algorithms Real-time routing for organs, aircraft, and teams. Live case tracking for hospital transplant teams. Match d

  9. Slide 9: Four Clear Growth Initiatives to Extend Growth and Expand TAM

    Four Clear Growth Initiatives to Extend Growth and Expand TAM 01 02 03 04 Drive Heart & Lung OCS Kidney Program EU Expansion Next-Gen OCS 3.0 9

  10. Slide 10: Drive U.S. Heart & Lung Penetration — Expanding Annual TAM in These Critical Segments

    Drive U.S. Heart & Lung Penetration — Expanding Annual TAM in These Critical Segments 01 Drive Heart & Lung Adoption UNTAPPED HEARTS TAM UNTAPPED LUNG TAM ENHANCE Heart & DENOVO Lung Studies designed to drive heart & ~2,200 ~3,200 lung adoption, expand annual DBD hearts ≤ 4 hours Lung transplants TA

  11. Slide 11: OCS Kidney — Unlocking the Largest Transplant Segment with Significant Cost Burden

    OCS Kidney — Unlocking the Largest Transplant Segment with Significant Cost Burden 02 ANNUAL COST BURDEN ADDRESSABLE VOLUME OCS Kidney Program ~21,000 OCS Kidney Annual U.S. transplants ~$10.3 B DISCARD POOL Annual U.S. waiting list Extends OCS into the largest ~9,100 Cost burden to CMS transplant s

  12. Slide 12: NOP Europe — Expanding the TAM with a Near-Identical Scale to the U.S. Opportunity

    NOP Europe — Expanding the TAM with a Near-Identical Scale to the U.S. Opportunity 03 ANNUAL TRANSPLANT VOLUMES • 2025 Kidney Liver Heart Lung EU Expansion ~40,764 U.S. ~37,533 EU NOP Europe 3,490 2,353 4,587 Replicates the U.S. NOP model in 11,635 2,738 9,244 Europe — near-doubling addressable tran

  13. Slide 13: OCS 3.0 — Next-gen OCS Platform Designed for Scale, Supply-Chain Independence, and Significant Operating Leverage

    OCS 3.0 — Next-gen OCS Platform Designed for Scale, Supply- Chain Independence, and Significant Operating Leverage 04 Scale Next-Gen OCS Platform Cloud-based control and monitoring OCS Gen-3.0 Leverage Cloud-connected, Lower part-count with robotic automated, sensor-integrated assembly – Lower COGS

  14. Slide 14: TransMedics Uniquely Positioned to Deliver Significant Shareholder Value

    TransMedics Uniquely Positioned to Deliver Significant Shareholder Value 01. CLINICAL EDGE 02. LARGE MOAT 03. GROWTH RUNWAY 04. EXECUTION EVIDENCE EVIDENCE EVIDENCE EVIDENCE Highest rate of organ National tech, services and Four clear and Mission-driven team utilization with superior logistics infra

TransMedics Group — Baird 2026 Global Healthcare Conference on 6ix